Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 57.00 | |
5 mg | In stock | $ 139.00 | |
10 mg | In stock | $ 197.00 | |
25 mg | In stock | $ 359.00 | |
50 mg | In stock | $ 597.00 | |
100 mg | In stock | $ 852.00 | |
500 mg | In stock | $ 1,730.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 148.00 |
Description | BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular. |
Synonyms | BMS 813160 |
Molecular Weight | 484.64 |
Formula | C25H40N8O2 |
CAS No. | 1286279-29-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (113.49 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BMS-813160 1286279-29-5 Immunology/Inflammation Microbiology/Virology CCR Inhibitor CC chemokine receptor dual antagonist BMS813160 peritonitis CD11b BMS 813160 inflammation CTX thioglycollate inhibit mouse oral inhibitor